US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Voyager Therapeutics, Inc. - Common Stock (NQ:VYGR)

2.450 -0.230 (-8.58%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Voyager Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Which stocks are moving after the closing bell on Friday? ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Voyager Therapeutics Alzheimer's Portfolio And ALPL NeuroShuttle Underscore Platform Momentum: Analyst ↗
Voyager's Alzheimer's programs show longer CNS exposure and potential gene therapy advances, with analysts maintaining a Buy rating and $30 price target. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
A Glimpse Into The Expert Outlook On Voyager Therapeutics Through 5 Analysts ↗
 
Via Benzinga
News headline image
Voyager Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 12, 2024 ↗
 
Via Benzinga
News headline image
Preview: Voyager Therapeutics's Earnings ↗
 
Via Benzinga
News headline image
7 Analysts Assess Voyager Therapeutics: What You Need To Know ↗
 
Via Benzinga
News headline image
Bragar Eagel & Squire, P.C. Is Investigating Dave, Red Cat, Perpetua, and Voyager and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
A Glimpse Into The Expert Outlook On Voyager Therapeutics Through 4 Analysts ↗
 
Via Benzinga
News headline image
VOYAGER ALERT: Bragar Eagel & Squire, P.C. is Investigating Voyager Therapeutics, Inc. on Behalf of Voyager Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
In-Depth Examination Of 4 Analyst Recommendations For Voyager Therapeutics ↗
 
Via Benzinga
News headline image
What Analysts Are Saying About Voyager Therapeutics Stock ↗
 
Via Benzinga
News headline image
Earnings Scheduled For March 11, 2025 ↗
 
Via Benzinga
News headline image
VYGR Investors Have Opportunity to Join Voyager Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
Is VOYAGER THERAPEUTICS INC (NASDAQ:VYGR) suited for growth investing? ↗
Should you consider VOYAGER THERAPEUTICS INC (NASDAQ:VYGR) for growth investing? 
Via Chartmill
News headline image
Is NASDAQ:VYGR a Fit for Growth Investing Strategies? ↗
High growth, ROE and relative strength for VOYAGER THERAPEUTICS INC (NASDAQ:VYGR), growth investors may appreciate this. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Get “Picky” With Stocks For September Profits ↗
Via Talk Markets
News headline image
3 High-Growth Stocks Poised To Double By Next Year ↗
The article outlines three high-growth stocks that could double by 2025, using specific screening criteria: strong buy ratings from multiple analysts, significant revenue and earnings growth, and... 
Via Talk Markets
News headline image
7 Biotech Stocks to Buy for Their Game-Changing Potential ↗
Although the market may be reeling from the recent fallout, the red ink presents a viable opportunity in these biotech stocks. 
Via InvestorPlace
News headline image
VYGR Stock Earnings: Voyager Therapeutics Beats EPS, Beats Revenue for Q2 2024 ↗
VYGR stock results show that Voyager Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Delving into NASDAQ:VYGR's Growth Prospects. ↗
Why VOYAGER THERAPEUTICS INC (NASDAQ:VYGR) qualifies as a high growth stock. 
Via Chartmill
News headline image
Exploring NASDAQ:VYGR's growth characteristics. ↗
VOYAGER THERAPEUTICS INC (NASDAQ:VYGR) may be suited for growth investing, we'll explore why in this article. 
Via Chartmill
News headline image
Is VOYAGER THERAPEUTICS INC (NASDAQ:VYGR) suited for growth investing? ↗
Unlocking the Growth Potential of VOYAGER THERAPEUTICS INC (NASDAQ:VYGR). 
Via Chartmill
News headline image
VYGR Stock Earnings: Voyager Therapeutics Beats EPS, Beats Revenue for Q1 2024 ↗
VYGR stock results show that Voyager Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
The Healthcare Bargain Blitz: 7 Undervalued Stocks to Inject into Your Portfolio ↗
With a possible rotation away from the technology space, these are the undervalued healthcare stocks to consider. 
Via InvestorPlace
News headline image
Cheap Thrills: 7 Promising Value Stocks You Can Buy for Under $20 ↗
With so many thousands of securities available, there are bound to be compelling ideas for value stocks under $20. 
Via InvestorPlace
News headline image
Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform ↗
Unlock potential with Voyager Therapeutics as HC Wainwright initiates coverage highlights its TRACER capsid platform, promising CNS-targeted gene therapies and strategic partnerships driving long-term... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >